IDYA on Nasdaq
Ideaya Biosciences (United States)
American pharmaceutical preparations company, incorporated in Delaware.1
Price unavailable
Last updated Oct 18, 2026.
Overview
2015Founded1
Compare with Vanda Pharmaceuticals Inc., Amarin Corporation or Puma Biotechnology, or pick any stock.
- TickerIDYA on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersDE1
- Websitewww.ideayabio.com
- Incorporated inDE3
- Business address5000 Shoreline Ct, Suite 300, South San Francisco, Ca 940803
- Filer categoryLarge accelerated filer3
See how the biggest companies compare on our leaderboards
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-72.8%Operating margin5
-52.0%Net margin5
3024.4%Revenue growth, 20255
-11.1%Return on equity5
-$73.5MFree cash flow5
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development100¢$314.7M
Out of $218.7M in revenue.5 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Collaboration revenue | $218.7M | $7.0M | $23.4M |
| Research and development | $314.7M | $294.7M | $129.5M |
| General and administrative | $63.3M | $39.3M | $28.3M |
| Total operating expenses | $378.0M | $334.0M | $157.8M |
| Loss from operations | -$159.3M | -$327.0M | -$134.4M |
| Interest income and other income, net | $45.6M | $52.5M | $21.5M |
| Net loss | -$113.7M | -$274.5M | -$113.0M |
| Unrealized gains on marketable securities | $1.5M | $250.0K | $3.4M |
| Comprehensive loss | -$112.2M | -$274.2M | -$109.5M |
| Net loss per common share, basic | -$1.28 | -$3.36 | -$1.96 |
| Net loss per common share, diluted | -$1.28 | -$3.36 | -$1.96 |
| Weighted-average number of common shares outstanding used in computing net loss per share, basic | 88.5M shares | 81.7M shares | 57.5M shares |
| Weighted-average number of common shares outstanding used in computing net loss per share, diluted | 88.5M shares | 81.7M shares | 57.5M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $112.8M | $84.4M | $157.0M | |
| Short-term marketable securities | $526.6M | $591.9M | ||
| Prepaid expenses and other current assets | $21.4M | $13.4M | ||
| Contract assets | $6.0M | $0 | ||
| Total current assets | $666.7M | $689.7M | ||
| Restricted cash | $1.0M | $805.0K | ||
| Long-term marketable securities | $410.3M | $405.8M | ||
| Property and equipment, net | $8.2M | $9.0M | ||
| Right-of-use assets | $23.1M | $18.8M | ||
| Total assets | $1.1B | $1.1B | ||
| Accounts payable | $17.6M | $15.4M | ||
| Accrued liabilities | $40.9M | $30.4M | ||
| Operating lease liabilities, current | $339.0K | $298.0K | ||
| Total current liabilities | $58.8M | $46.1M | ||
| Long-term operating lease liabilities | $27.6M | $18.9M | ||
| Total liabilities | $86.4M | $64.9M | ||
| Common stock, $0.0001 par value, 300,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 87,796,561 and 86,503,509 shares issued and outstanding as of December 31, 2025 and December 31, 2024 | $9.0K | $9.0K | ||
| Additional paid-in capital | $1.8B | $1.7B | ||
| Accumulated other comprehensive income | $2.3M | $812.0K | ||
| Accumulated deficit | -$736.5M | -$622.8M | ||
| Total stockholders equity | $1.0B | $1.1B | $621.1M | $349.5M |
| Total liabilities and stockholders equity | $1.1B | $1.1B | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, shares authorized | 300.0M shares | 300.0M shares | ||
| Common stock, shares issued | 87.8M shares | 86.5M shares | ||
| Common stock, shares outstanding | 87.8M shares | 86.5M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $112.8M | $84.4M | $157.0M | |
| Short-term marketable securities | $526.6M | $591.9M | ||
| Prepaid expenses and other current assets | $21.4M | $13.4M | ||
| Contract assets | $6.0M | $0 | ||
| Total current assets | $666.7M | $689.7M | ||
| Restricted cash | $1.0M | $805.0K | ||
| Long-term marketable securities | $410.3M | $405.8M | ||
| Property and equipment, net | $8.2M | $9.0M | ||
| Right-of-use assets | $23.1M | $18.8M | ||
| Total assets | $1.1B | $1.1B | ||
| Accounts payable | $17.6M | $15.4M | ||
| Accrued liabilities | $40.9M | $30.4M | ||
| Operating lease liabilities, current | $339.0K | $298.0K | ||
| Total current liabilities | $58.8M | $46.1M | ||
| Long-term operating lease liabilities | $27.6M | $18.9M | ||
| Total liabilities | $86.4M | $64.9M | ||
| Common stock, $0.0001 par value, 300,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 87,796,561 and 86,503,509 shares issued and outstanding as of December 31, 2025 and December 31, 2024 | $9.0K | $9.0K | ||
| Additional paid-in capital | $1.8B | $1.7B | ||
| Accumulated other comprehensive income | $2.3M | $812.0K | ||
| Accumulated deficit | -$736.5M | -$622.8M | ||
| Total stockholders equity | $1.0B | $1.1B | $621.1M | $349.5M |
| Total liabilities and stockholders equity | $1.1B | $1.1B | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, shares authorized | 300.0M shares | 300.0M shares | ||
| Common stock, shares issued | 87.8M shares | 86.5M shares | ||
| Common stock, shares outstanding | 87.8M shares | 86.5M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$113.7M | -$274.5M | -$113.0M |
| Depreciation and amortization | $2.7M | $2.4M | $2.5M |
| Net amortization (accretion) of premiums (discounts) on marketable securities | -$10.0M | -$23.2M | -$11.6M |
| Stock-based compensation | $46.1M | $34.7M | $18.5M |
| Amortization of right of use assets | $1.9M | $1.4M | $1.5M |
| Accounts receivable | $0 | $0 | $193.0K |
| Prepaid expenses and other assets | -$7.8M | -$6.2M | -$2.0M |
| Accounts payable | $2.7M | $8.3M | $2.6M |
| Accrued and other liabilities | $10.4M | $10.8M | $1.6M |
| Contract assets and liabilities | -$6.0M | $0 | -$13.8M |
| Lease liabilities | $2.6M | -$1.4M | -$1.9M |
| Net cash used in operating activities | -$71.1M | -$247.6M | -$115.2M |
| Purchases of property and equipment, net | -$2.4M | -$3.9M | -$2.4M |
| Purchases of marketable securities | -$607.9M | -$1.2B | -$596.0M |
| Maturities of marketable securities | $680.2M | $692.6M | $439.9M |
| Net cash provided by (used in) investing activities | $70.0M | -$502.6M | -$158.5M |
| Proceeds from issuance of common stock in public offering, net of issuance costs | $0 | $274.4M | $281.2M |
| Proceeds from issuances of pre-funded warrants | $0 | $9.4M | $42.2M |
| Proceeds from issuance of common stock related to at-the-market offering program, net of issuance costs | $24.9M | $379.9M | $28.6M |
| Proceeds from exercise of common stock options | $3.4M | $12.5M | $9.6M |
| Proceeds from ESPP purchases | $1.5M | $1.4M | $1.2M |
| Net cash provided by financing activities | $29.8M | $677.6M | $362.7M |
| Net increase (decrease) in cash, cash equivalents and restricted cash | $28.7M | -$72.6M | $89.0M |
| Cash paid for interest | $0 | $25.0K | $69.0K |
| Right-of-use asset obtained in exchange for a new operating lease liability | $6.2M | $18.0M | $1.3M |
| Purchases of property and equipment in accounts payable and accrued liabilities | $1.1M | $1.5M | $147.0K |
| Unpaid offering costs | $0 | $0 | $43.0K |
No quarter-by-quarter statement was filed.
Compare Ideaya Biosciences (United States) with another company
Leadership
Who has led Ideaya Biosciences (United States), and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
20202025
- Chief executive officerYujiro S. Hata May 22, 2019 to now13
- PresidentYujiro S. Hata May 22, 2019 to now13
- Chief financial officerJoshua Bleharski Jun 27, 2025 to now14
Board members and other officers (21)
- Chief Development OfficerTheodora Ross Jun 5, 2026 to now15
- Chief Commercial OfficerStuart Dorman Dec 20, 2024 to now16
- OfficerBriseno Andres Ruiz Jul 3, 2023 to now17
- SVP, Chief Medical OfficerDarrin Beaupre Dec 14, 2022 to now18
- SVP, Chief Scientific OfficerMichael Anthony White Oct 27, 2021 to now19
- SVP, Chief Technology OfficerJeffrey Hager May 22, 2019 to Jul 30, 201920
- SVP, Chief Medical OfficerJulie Hambleton May 22, 2019 to Feb 25, 202021
- SVP, Head of BiologyMark Lackner May 22, 2019 to Feb 26, 202122
- SVP, Chief Scientific OfficerMichael P. Dillon May 22, 2019 to Oct 7, 202123
- Board memberCatherine J. Mackey Apr 6, 2022 to now24
- Board memberSusan L. Kelley Feb 17, 2021 to May 31, 202425
- Board memberMalcolm Garret Hampton Jun 30, 2020 to now26
- Board memberJohn D. Diekman May 22, 2019 to Dec 19, 201927
- Board memberScott W. Morrison May 22, 2019 to now28
- Board memberTerry J. Rosen May 22, 2019 to now29
- Board memberThilo Schroeder May 22, 2019 to May 22, 201930
- Board memberTimothy M. Shannon May 22, 2019 to Jun 9, 202331
- Board memberYujiro S. Hata May 22, 2019 to now13
- Board memberWendy L. Yarno Dec 19, 2019 to now32
- General counselDouglas B. Snyder Sep 27, 2024 to now33
- General counselJason Throne Oct 11, 2019 to Jun 27, 202434
Timeline
Filings
305 filings to the SEC since October 2021: 5 annual reports, 16 quarterly reports, 74 major events, 105 insider forms, 52 large holders, 53 other. The latest 20:
- Oct 8, 20264 EDGAR
- Oct 6, 2026144 EDGAR
- Aug 14, 2026SCHEDULE 13G EDGAR
- Aug 4, 202610-Q EDGAR
- Aug 4, 20268-K EDGAR
- Jul 31, 2026SCHEDULE 13G EDGAR
- Jul 9, 20264 EDGAR
- Jul 7, 2026144 EDGAR
- Jun 23, 20268-K EDGAR
- Jun 18, 20264 EDGAR
- Jun 18, 20264 EDGAR
- Jun 18, 20264 EDGAR
- Jun 18, 20264 EDGAR
- Jun 18, 20264 EDGAR
- Jun 18, 20264 EDGAR
- Jun 10, 20268-K EDGAR
- Jun 9, 2026424B5 EDGAR
- Jun 8, 2026424B5 EDGAR
- Jun 5, 20263 EDGAR
- Jun 3, 20268-K EDGAR
The 305 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 52 such filings since October 2021, the latest 10:
- Aug 14, 2026SCHEDULE 13G
- Jul 31, 2026SCHEDULE 13G
- May 15, 2026SCHEDULE 13G/A
- Mar 27, 2026SCHEDULE 13G/A
- Feb 17, 2026SCHEDULE 13G/A
- Feb 12, 2026SCHEDULE 13G/A
- Jan 8, 2026SCHEDULE 13G/A
- Nov 14, 2025SCHEDULE 13G/A
- Aug 14, 2025SCHEDULE 13G/A
- Aug 13, 2025SCHEDULE 13G
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Fmr LLC | 14,109,431 | $525.9M | 0.0% | +937,328 |
| BlackRock, Inc. | 8,893,260 | $331.5M | 0.0% | +451,127 |
| Jupiter Topco LLC | 8,579,881 | $319.7M | 0.1% | New |
| Capital Research Global Investors | 5,344,701 | $199.2M | 0.0% | +181,158 |
| Baker Bros. Advisors LP | 5,010,030 | $186.7M | 0.9% | +1,063,515 |
| State Street Corp | 4,548,911 | $169.5M | 0.0% | +767,744 |
| Vanguard Capital Management LLC | 4,132,646 | $154.0M | 0.0% | +400,224 |
| Logos Global Management LP | 3,000,000 | $111.8M | 4.8% | −450,000 |
| Adage Capital Partners Gp, L.l.c. | 2,715,391 | $101.2M | 0.1% | −108,109 |
| Deerfield Management Company, L.P. | 2,714,503 | $101.2M | 1.3% | +1,184,495 |
| Geode Capital Management, LLC | 2,425,602 | $90.4M | 0.0% | −75,122 |
| Morgan Stanley | 1,931,491 | $72.0M | 0.0% | +71,038 |
| Dimensional Fund Advisors LP | 1,661,281 | $61.9M | 0.0% | +327,803 |
| Alliancebernstein L.P. | 1,627,521 | $54.2M | 0.0% | +1,526,735 |
| Fiera Capital Corp | 1,445,885 | $53.9M | 0.2% | −1,081,191 |
| Federated Hermes, Inc. | 1,431,630 | $53.4M | 0.1% | −1,555,477 |
| GSK plc | 1,333,333 | $49.7M | 8.3% | No change |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1,269,889 | $47.3M | 0.0% | +168,744 |
| Goldman Sachs Group Inc | 1,231,614 | $45.9M | 0.0% | −424,003 |
| Candriam S.C.A. | 1,092,301 | $40.7M | 0.2% | −15,407 |
| Bank Of America Corp /de/ | 1,026,143 | $38.2M | 0.0% | +84,052 |
| Sofinnova Investments, Inc. | 925,119 | $34.5M | 1.8% | −206,667 |
| Arrowstreet Capital, Limited Partnership | 891,608 | $33.2M | 0.0% | New |
| Fisher Asset Management, LLC | 851,306 | $31.7M | 0.0% | −31,393 |
| Vanguard Portfolio Management LLC | 821,612 | $30.6M | 0.0% | +76,019 |
13F reports cover disclosed long positions in U.S. stocks only.
Links
- Websitewww.ideayabio.com1
- WikidataQ104481192
- SEC EDGARCIK 1676725
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4Company websiteIdeaya Biosciences (United States) photo
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17SEC EDGARBriseno Andres Ruiz, Officer
- 18
- 19
- 20
- 21
- 22SEC EDGARMark Lackner, SVP, Head of Biology
- 23
- 24SEC EDGARCatherine J. Mackey, Board member
- 25SEC EDGARSusan L. Kelley, Board member
- 26SEC EDGARMalcolm Garret Hampton, Board member
- 27SEC EDGARJohn D. Diekman, Board member
- 28SEC EDGARScott W. Morrison, Board member
- 29SEC EDGARTerry J. Rosen, Board member
- 30SEC EDGARThilo Schroeder, Board member
- 31SEC EDGARTimothy M. Shannon, Board member
- 32SEC EDGARWendy L. Yarno, Board member
- 33SEC EDGARDouglas B. Snyder, General counsel
- 34SEC EDGARJason Throne, General counsel